SCHEMBL26128656

SCHEMBL26128656

Nc1nn(C(c2ccccc2)(c2ccccc2)c2ccccc2)c2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.40
HTT P42858 1/20 0.39
PDGFRA P16234 1/20 0.38
CDK5 Q00535 1/20 0.38
TYRO3 Q06418 1/20 0.38
ADORA2A P29274 2/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
PDPK1 O15530 2/20 0.35
JAK2 O60674 2/20 0.35
ELANE P08246 2/20 0.34
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
DYRK1A Q13627 2/20 0.33
NPC1 O15118 2/20 0.33
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17848185 0.88 PDGFRA (0.47) ADRB2HTTPDGFRACDK5TYRO3
SCHEMBL30084144 0.82 ELANE (0.34) ADRB2HTTADORA2AADORA3ADORA2B
SCHEMBL27790903 0.81 TTK (0.36) HTTADORA2AADORA3ADORA1NPC1
SCHEMBL19678623 0.79 ELANE (0.35) HTTELANECYP1A2KDM4ESMN1; SMN2
SCHEMBL4143502 0.79 ELANE (0.45) ELANEPLA2G2A
SCHEMBL26390731 0.79 ELANE (0.38) ADRB2HTTELANEKDM4ESMN1; SMN2
SCHEMBL26131956 0.77 MAPK1 (0.34) ADRB2HTTADORA2AADORA3ADORA1
SCHEMBL590715 0.77 HTR6 (0.38) MAPTKDM4ESMN1; SMN2
SCHEMBL2732363 0.77 DCLK1 (0.40) ELANECYP1A2DYRK1ADCLK1PRKD3
SCHEMBL12373963 0.77 CNR1 (0.39) HTTCDK5DYRK1ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2025-06-26 US disclosed
EP-4499612-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2025-02-05 EP disclosed
CN-118974020-A Substituted 3-aminoindazole derivatives as kinase inhibitors 内尔维亚诺医疗科学公司 2024-11-15 CN disclosed
WO-2023186773-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206724-A1 SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS CDK1, CDK11A, CDK3 ADRB2 4423/4885HTT 4297/4885PDGFRA 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.